Phase I Dose Escalating Study Of Tas-106 In Combination With Carboplatin In Patients With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 17 Oct 2012
At a glance
- Drugs Carboplatin; TAS 106
- Indications Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 May 2012 Planned end date changed from 1 Sep 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 25 Nov 2011 Planned end date changed from 1 Sep 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.